🔗 Permalink

Assignee profile:

Newave Pharmaceutical Inc.

City:

Pleasanton, California

Country:

United States

Published Applications:

Last publication date:

2025-03-06

Patent Grants:

Last grant date:

2026-03-10

Top Inventors for applications by Newave Pharmaceutical Inc.

These are the the leading inventors for applications assigned to Newave Pharmaceutical Inc.:

Yi Chen 22 Pleasanton, CA United States
Yan Lou 11 Pleasanton, CA United States
Yan Lou 1 Pleasonton, CA United States

Recent patent applications by Newave Pharmaceutical Inc.

Newave Pharmaceutical Inc. based in Pleasanton, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2025-03-06 ✅ Patent 12,569,564 granted on 2026-03-10

US20250073340A1

Human necessities

SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF

#2 | 2024-02-22

US20240058457A1

Human necessities

BTK DEGRADER

#3 | 2023-08-31 ✅ Patent 12,410,190 granted on 2025-09-09

US20230271979A1

Chemistry; metallurgy

CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES

#4 | 2023-05-04 ✅ Patent 12,086,788 granted on 2024-09-10

US20230140433A1

Physics

Substituted pyrazines as inhibitors of BTK, and mutants thereof

#5 | 2023-04-20 ✅ Patent 12,552,784 granted on 2026-02-17

US20230119463A1

Chemistry; metallurgy

1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES

#6 | 2022-12-22 ✅ Patent 11,993,610 granted on 2024-05-28

US20220402941A1

Chemistry; metallurgy

BCL-2 inhibitors

#7 | 2022-11-17 ✅ Patent 12,747,251 granted on 2026-09-29

US20220363689A1

Chemistry; metallurgy

INHIBITOR OF BTK AND MUTANTS THEREOF

#8 | 2022-07-14 ✅ Patent 11,680,072 granted on 2023-06-20

US20220220126A1

Chemistry; metallurgy

Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases

#9 | 2022-05-05 ✅ Patent 12,637,467 granted on 2026-05-26

US20220135569A1

Chemistry; metallurgy

INHIBITOR OF BTK AND MUTANTS THEREOF

#10 | 2022-03-10 ✅ Patent 12,583,853 granted on 2026-03-24

US20220073513A1

Chemistry; metallurgy

1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES

#11 | 2021-10-28 ✅ Patent 11,903,950 granted on 2024-02-20

US20210332065A1

Chemistry; metallurgy

BCL-2 inhibitors

#12 | 2021-10-14 ✅ Patent 12,220,419 granted on 2025-02-11

US20210315904A1

Human necessities

BCL-2 inhibitors

#13 | 2021-03-04 ✅ Patent 11,479,555 granted on 2022-10-25

US20210061807A1

Chemistry; metallurgy

Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase

#14 | 2020-12-03 ✅ Patent 11,501,284 granted on 2022-11-15

US20200377478A1

Chemistry; metallurgy

Substituted pyrazines as inhibitors of BTK, and mutants thereof

#15 | 2020-06-25 ✅ Patent 11,365,206 granted on 2022-06-21

US20200197406A1

Human necessities

BCL-2 inhibitors

#16 | 2020-06-18 ✅ Patent 11,279,711 granted on 2022-03-22

US20200190109A1

Chemistry; metallurgy

Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases

#17 | 2019-06-06 ✅ Patent 10,501,456 granted on 2019-12-10

US20190169182A1

Chemistry; metallurgy

Therapeutic agents for the treatment of HBV infection

#18 | 2019-05-23 ✅ Patent 10,456,397 granted on 2019-10-29

US20190151316A1

Human necessities

Covalent inhibitors of CDK-7

#19 | 2019-02-07 ✅ Patent 10,377,755 granted on 2019-08-13

US20190040062A1

Chemistry; metallurgy

BCL-2 inhibitors

#20 | 2018-06-21 ✅ Patent 10,239,872 granted on 2019-03-26

US20180170925A1

Chemistry; metallurgy

Therapeutic agents for the treatment of HBV infection

#21 | 2018-01-11 ✅ Patent 10,195,200 granted on 2019-02-05

US20180008604A1

Human necessities

Covalent inhibitors of CDK-7

#22 | 2017-10-26 ✅ Patent 10,253,029 granted on 2019-04-09

US20170305918A1

Chemistry; metallurgy

Dual-warhead covalent inhibitors of FGFR-4

Also check out Newave Pharmaceutical Inc.'s (Pleasanton, United States) applicant profile with 37 patent applications submitted.

AssigneeID:

347651 ⎘